Complementary and alternative medicine in urology

BJU International

Volumn 96, Issue 8, 2005, Pages 1177-1184

  Dreikorn, Kurt ^a  

^a KLINIKUM BREMEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; CAROTENOID; CUCURBITA PEPO EXTRACT; FATTY ACID; HERBACEOUS AGENT; HYPOXIS ROOPERI EXTRACT; ISOFLAVONE; LECTIN; LUPEOL; MINERAL; PHYTOESTROGEN; PHYTOSTEROL; PICEA EXTRACT; PLANT EXTRACT; POLYSACCHARIDE; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CEREALE EXTRACT; SELENIUM; TERPENOID; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; VEGETABLE OIL; VITAMIN;

ALTERNATIVE MEDICINE; CANCER; CRANBERRY; DIET; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; FRUIT JUICE; HEALTH; HEALTH BEHAVIOR; HEALTH CARE AVAILABILITY; HERBAL MEDICINE; HUMAN; HYPOXIS; LIFESTYLE; MANIPULATIVE MEDICINE; MEDICAL RESEARCH; NUTRITION; PHYTOTHERAPY; PINE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATITIS; PUMPKIN; RED WINE; REVIEW; RYE; URINARY TRACT DISEASE; UROLOGY; WELLBEING;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FEMALE UROGENITAL DISEASES; HUMANS; MALE UROGENITAL DISEASES; MINERALS; PHYTOTHERAPY; VACCINIUM MACROCARPON; VITAMINS; WINE;

EID: 28444442695     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05931.x     Document Type: Review

References (53)

1. Fair WR. Back to the future - the role of complementary medicine in urology. J Urol 1999; 162: 411-20
2. Moyad MA. Complementary medicine in urology. Urol Clin N Am 2002; 29: xv-xvi
3. Zimmerman RA, Thompson IM. Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis and use among prostate cancer patients. Urol Clin N Am 2002; 29: 1-9
4. Doggweiler-Wiygul R. Complementary medicine in urology - a different approach. World J Urol 2002; 20: 271-318
5. McClure MW. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. World J Urol 2002; 20: 273-84
6. The United Kingdom Parliament. House of Lords. Science and Technology-Sixth Report 21 November 2000 http://www.parliament.the-stationery- office.co.uk/pa/ld199900/ldselect/ldsctech/123/12301.htm
7. Department of Health. Government Response to the House of Lords Select Committee on Science and Technology's Report on complementary and alternative medicine, March 2001 http://www.archive.official-documents.co.uk/document/cm51/ 5124/5124.pdf
8. Dacgnelie PD, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 2004; 93: 1139-50
9. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004; 14: 143-9
10. Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? BJU Int 2005; 96: 231-2
11. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170-8
12. NIH. http//nccam.nih.gov/health/alerts/spes/
13. Oh WK, Small EJ. PC-SPES and prostate cancer. Urol Clin N Am 2002; 29: 59-66
14. Mydlo JH. The impact of obesity in urology. Urol Clin N Am 2004; 31: 275-87
15. Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 2002; 59: 41-50
16. Moyad MA. Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer? Urol Clin N Am 2002; 29: 115-24
17. Moyad MA, Caroll PR. Lifestyle recommendations to prevent prostate cancer. Part I. Time to redirect our attention? Urol Clin N Am 2004; 31: 289-300
18. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer. Part II. Time to redirect our attention? Urol Clin N Am 2004; 31: 301-11
19. Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless. Part I. Urol Clin N Am 2004; 31: 249-57
20. Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless. Part II. Urol Clin N Am 2004; 31: 259-73
21. Gupta S, Mukhtar H. Green tea and prostate cancer. Urol Clin N Am 2002; 29: 49-57
22. Wilt TJ, Ishani A, Stark G et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
23. Wilt TJ. Phytotherapy. In Chapple CR, McConnell JD, Tubaro A eds. Benign Prostatic Hyperplasia. London: Martin Dunitz, 2000: 39-63
24. Dreikorn K, Lowe FC, Borkowski A et al. Other medical therapies. In Chatelain C, Denis L, Foo KT, Khoury S, McConnel JD eds. Benign Prostatic Hyperplasia. Plymouth: Plymbridge Distributors Ltd, 2001: 479-511
25. Dreikorn K, Berges R, Pientka L, Jonas M. Phytotherapie bei BPH. Aktuelle evidenzbasierte Bewertung. Urologe [a] 2002; 41: 447-51
26. Madersbacher S, Schatzl G, Brössner C, Dreikorn K. Phytotherapie bei BPS. Urologe [a] 2005; 44: 513-20
27. Dreikorn K, Fitzpatrick JM. Phytotherapeutic agents in the treatment of LUTS and BPH. In Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P eds, Textbook of Benign Prostatic Hyperplasia. London and New York: Taylor & Francis, 2005: 415-27
28. Fagelman EF, Lowe FC. Herbal medications in the treatment of benign prostatic hyperplasia (BPH). Urol Clin N Am 2002; 29: 23-9
29. Nelson MA, Reid M, Duffield-Lillico AJ, Marshall JR. Prostate cancer and selenium. Urol Clin N Am 2002; 29: 67-70
30. Clark LC, Combs GF Jr, Turnbull BW et al. For the Nutritional Prevention of Cancer Study Group: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomised clinical trial. JAMA 1996; 76: 1957-66
31. Clark LC, Dodkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation, results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730-4
32. Duffield-Lillico AJ, Dalkin BL, Reid ME et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91: 608-12
33. Fleshner NE. Vitamin E and prostate cancer. Urol Clin N Am 2002; 29: 107-13
34. Moyad MA. Selenium and vitamin E supplements for prostate cancer: Evidence or embellishment? Urology 2002; 59 (Suppl. 4A): 9-19
35. Hyman M, Pizzorno J, Weil A. A rational approach to antioxidant therapy and vitamin E. Alternative Therapies 2005; 11: 14-7
36. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35
37. Heinonen OP, Albanes D, Virtomo J et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440-6
38. The HOPE and HOPE-TOO Trial Investigators. Effects of long term vitamin E supplementation on cardiovascular events and cancer. A randomised controlled trial. JAMA 2005; 293: 1138-347
39. Miller ER, Pastor-Barriuso R, Dalod D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46
40. Guallar E, Hanley DF, Miller ER III. An editorial update: Annus horribilis for vitamin E. Ann Int Med 2005; 143: 143-5
41. Greenberg ER. Editorial: Vitamin E supplements: Good in theory, but is the theory good? Ann Intern Med 2005; 142: 75-6
42. Anonymous. Letter to the editor. Ann Intern Med 2005; 143: 150-8
43. Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999; 281: 1110-1
44. Lee I-Min, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer. JAMA 2005; 294: 56-65
45. Cook NR, Stampfer MJ, Ma J et al. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999; 86: 1783-92
46. Malila N, Taylor PR, Virtonen MJ et al. Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland) Cancer Causes Control 2002; 13: 617-23
47. Miller EC, Giovannucci E, Erdmann JW, Bahnson R, Schwartz SJ, Clinton SK. Tomato products, lycopene, and prostate cancer risk. Urol Clin N Am 2002; 20: 83-93
48. Castle EP, Thrasher B. The role of soy phytoestrogens in prostate cancer. Urol Clin N Am 2002; 29: 71-81
49. Leitzmann MF, Stampfer MJ, Wu K, Colditz Ga Willet WC, Giovannucci EL. Zine supplement use and risk of prostate cancer. J Nat Cancer Inst 2003; 95: 1004-7
50. Yarnell E. Botanical medicines for the urinary tract. World J Urol 2002; 20: 285-93
51. Schoonen WM, Salinas CA, Kiemeney ALM, Stomford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 2005; 113: 133-40
52. Webb PM, Pundie DM, Bain CJ. Alcohol, wine and risk of epithelial ovarian cancer. Cancer Epidem Biom Prevent 2004; 13: 592-9
53. Briggs NC, Levine RS, Bobo LD. Wine drinking and risk of non-Hodgkin's lymphoma among men in the United States: a population-based study. Am J Epidem 2002; 156: 454-62